Justin Walsh
Stock Analyst at Jones Trading
(3.40)
# 921
Out of 5,173 analysts
39
Total ratings
45.71%
Success rate
24.74%
Average return
Main Sectors:
Stocks Rated by Justin Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NMTC NeuroOne Medical Technologies | Initiates: Buy | $1.5 | $0.78 | +92.31% | 1 | Mar 2, 2026 | |
| LNTH Lantheus Holdings | Downgrades: Hold | n/a | $76.43 | - | 11 | Feb 27, 2026 | |
| ATAI AtaiBeckley | Initiates: Buy | $16 | $3.49 | +358.45% | 1 | Dec 23, 2025 | |
| PRAX Praxis Precision Medicines | Initiates: Buy | $83 | $298.31 | -72.18% | 1 | Sep 18, 2025 | |
| VNRX VolitionRx | Initiates: Buy | $3 | $0.19 | +1,503.42% | 1 | Jun 10, 2025 | |
| BLRX BioLineRx | Upgrades: Buy | $12 | $2.65 | +352.83% | 3 | May 30, 2025 | |
| CLNN Clene | Initiates: Buy | $30 | $5.33 | +463.38% | 1 | Apr 23, 2025 | |
| MNPR Monopar Therapeutics | Downgrades: Hold | n/a | $55.21 | - | 1 | Apr 2, 2025 | |
| SER Serina Therapeutics | Initiates: Buy | $11 | $2.54 | +333.07% | 1 | Mar 11, 2025 | |
| ANRO Alto Neuroscience | Initiates: Buy | $18 | $21.47 | -16.16% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $27.08 | +55.10% | 1 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $22 | $4.45 | +394.38% | 2 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $3.93 | +307.12% | 1 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $4.00 | +400.00% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $4 | $0.66 | +506.06% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $3.52 | +468.18% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $360 | $12.04 | +2,890.03% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $0.25 | +30,154.13% | 1 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $20 | $33.28 | -39.90% | 1 | May 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $440 → $200 | $0.77 | +25,833.61% | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $5.15 | +94.17% | 1 | Jan 19, 2022 |
NeuroOne Medical Technologies
Mar 2, 2026
Initiates: Buy
Price Target: $1.5
Current: $0.78
Upside: +92.31%
Lantheus Holdings
Feb 27, 2026
Downgrades: Hold
Price Target: n/a
Current: $76.43
Upside: -
AtaiBeckley
Dec 23, 2025
Initiates: Buy
Price Target: $16
Current: $3.49
Upside: +358.45%
Praxis Precision Medicines
Sep 18, 2025
Initiates: Buy
Price Target: $83
Current: $298.31
Upside: -72.18%
VolitionRx
Jun 10, 2025
Initiates: Buy
Price Target: $3
Current: $0.19
Upside: +1,503.42%
BioLineRx
May 30, 2025
Upgrades: Buy
Price Target: $12
Current: $2.65
Upside: +352.83%
Clene
Apr 23, 2025
Initiates: Buy
Price Target: $30
Current: $5.33
Upside: +463.38%
Monopar Therapeutics
Apr 2, 2025
Downgrades: Hold
Price Target: n/a
Current: $55.21
Upside: -
Serina Therapeutics
Mar 11, 2025
Initiates: Buy
Price Target: $11
Current: $2.54
Upside: +333.07%
Alto Neuroscience
Dec 16, 2024
Initiates: Buy
Price Target: $18
Current: $21.47
Upside: -16.16%
Oct 18, 2024
Initiates: Buy
Price Target: $42
Current: $27.08
Upside: +55.10%
May 16, 2024
Maintains: Buy
Price Target: $15 → $22
Current: $4.45
Upside: +394.38%
May 10, 2024
Initiates: Buy
Price Target: $16
Current: $3.93
Upside: +307.12%
Apr 17, 2024
Initiates: Buy
Price Target: $20
Current: $4.00
Upside: +400.00%
Sep 7, 2023
Reinstates: Buy
Price Target: $4
Current: $0.66
Upside: +506.06%
Sep 6, 2023
Initiates: Buy
Price Target: $20
Current: $3.52
Upside: +468.18%
May 16, 2023
Initiates: Buy
Price Target: $360
Current: $12.04
Upside: +2,890.03%
Oct 7, 2022
Initiates: Buy
Price Target: $75
Current: $0.25
Upside: +30,154.13%
May 20, 2022
Maintains: Buy
Price Target: $17 → $20
Current: $33.28
Upside: -39.90%
Apr 5, 2022
Maintains: Buy
Price Target: $440 → $200
Current: $0.77
Upside: +25,833.61%
Jan 19, 2022
Initiates: Buy
Price Target: $10
Current: $5.15
Upside: +94.17%